April 2022 PMID 35108059

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

David R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, David Vicente, David Planchard, Luis Paz-Ares, Johan F Vansteenkiste, Marina C Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Özgüroğlu, Ki H Lee, Terufumi Kato

Full text PDF Download social card

Mentions

169

Peak: 108 in Feb 2022

across 5 sources since Feb 2022

Extended reach

644,643

potential audience

Total likes

319

Video views

Mentions per month

Feb 2022 – Jun 2024

Where it's discussed

X / Twitter140 posts
News22 articles
Blogs3 articles
YouTube2 videos
Facebook2 posts

AI synopsis

What people are saying

The discussions prominently feature specific survival statistics, such as 42.9% five-year overall survival, and highlight the significance of the PACIFIC trial's updates, with phrases like 'long-term survival benefit' and 'game-changing' conveying strong positive sentiment and impactful insights into treatment advancements.

AgreementStrong agreement

Most discussions strongly support the findings, highlighting the long-term survival benefits of durvalumab in unresectable stage III NSCLC.

InterestHigh interest

Participants show high curiosity, sharing detailed data and updates from the PACIFIC trial, indicating deep engagement with the research.

EngagementHigh engagement

Many comments delve into specifics such as survival rates, HR values, and follow-up durations, demonstrating active involvement.

ImpactHigh impact

The broad sharing of trial updates and the emphasis on the clinical significance suggest users perceive this research as having substantial influence on treatment practices.

Abstract in brief

The PACIFIC trial showed that durvalumab significantly improves overall survival (OS) and progression-free survival (PFS) in patients with unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy, compared to placebo, with survival benefits lasting up to about 5 years.
Patients receiving durvalumab had a median OS of approximately 4.75 months and a 5-year OS rate around 42.9%, while median PFS was about 16.9 months with a 5-year PFS rate of roughly 33%.
The safety profile of durvalumab was manageable, and the results demonstrate a consistent, long-term survival benefit, supporting durvalumab as a valuable consolidation therapy after chemoradiotherapy in this patient group.

Read the full abstract

All mentions

Durvalumab Extends Survival in Stage III Non-Small Cell Lung Cancer

The PACIFIC trial showed durvalumab significantly improves overall and progression-free survival in unresectable stage III NSCLC patients post-chemoradiotherapy, with survival benefits lasting up to around 5 years…

Friends & Family 4 Health Equity · Jul 3, 2022 39 views

Long-Term Survival Benefits of Durvalumab in Stage III Lung Cancer

The PACIFIC trial demonstrated that durvalumab significantly improves overall and progression-free survival in unresectable stage III non-small cell lung cancer patients after chemoradiotherapy, with benefits lasting up…

Donna Willis, MD, MPH · Jul 3, 2022 11 views

Edu Hortelano

@eduhor82 · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | Journal of Clinical Oncology https://t.co/GfBi6NZ2RF

Jun 23, 2024 · 989 followers View post →

Johan Pluvy

@johanpluvy · X

Rappel PFS historique bras placebo : 5,6 mois ++ & OS à 3 ans bras placebo : 43,6% après RTCT conco https://t.co/dpqQlOO3T3 La population PDL1 neg ou inconnu et les patients ayant une radiothérapie séquentielle semblent donc en bénéficier en vie réelle.

Jun 9, 2024 · 122 followers View post →

Hiroshi Takumida

@HTakumida · X

https://t.co/2mV8vQq6tY というわけで見ていますが、OSに関してはまだ打ち切りが多いもののPACIFICのOS https://t.co/LIYApZlIKh と似たような雰囲気でしょうか。おおよそ10％の差がついてそのままその差が縮まらない。開いてくるわけじゃないんですよね。

Jun 6, 2024 · 1 like · 845 followers View post →

Oncology Brothers

@OncBrothers · X

RT @SamuelKareffMD: We embarked on this project using 5-year outcomes data from the #PACIFIC trail, noting that #durvalumab was cost-effect…

May 31, 2024 · 2 shares · 18,834 followers View post →

gilberto lopes

@GlopesMd · X

RT @SamuelKareffMD: We embarked on this project using 5-year outcomes data from the #PACIFIC trail, noting that #durvalumab was cost-effect…

May 31, 2024 · 2 shares · 37,602 followers View post →

Samuel Kareff, MD, MPH

@SamuelKareffMD · X

We embarked on this project using 5-year outcomes data from the #PACIFIC trail, noting that #durvalumab was cost-effective from the perspective of the US, Switzerland, and PRC previously

May 31, 2024 · 5 likes · 2 shares · 1,266 followers View post →

LungCancerRx

@LungCancerRx · X

RT @ADesaiMD: @SoMeCME @LealTiciana @KHigginsMD @ecoG @npennells34 @OncoAlert @LungCancerRx @IASLC @peters_solange @JhanelleGray @JackWestM…

Dec 19, 2023 · 1 share · 874 followers View post →

Aakash Desai, MD, MPH, FASCO

@ADesaiMD · X

@SoMeCME @LealTiciana @KHigginsMD @ecoG @npennells34 @OncoAlert @LungCancerRx @IASLC @peters_solange @JhanelleGray @JackWestMD @RamalingamMD @BrunaPellini @chulkimMD @Joshua_Reuss For @HemOncFellows @LungCancerRx, major strides in this field include: concurrent CRT > RT alone and the incorporation of #durvalumab consolidation post CRT!

Dec 19, 2023 · 4 likes · 1 share · 6,374 followers View post →

Drew Moghanaki

@DrewMoghanaki · X

These findings aren't surprising given the PACIFIC study group published a cursory analysis on this topic just last year in their 5-year update. https://t.co/SBRyjqQ0hu https://t.co/EvHj13lkRU

Apr 2, 2023 · 6 likes · 1 share · 12,958 followers View post →

chadi nabhan MD, MBA, FACP

@chadinabhan · X

@AaronGoodman33 @ASkarbnik I don’t recall mentioning this now did I? There was no mention of pancreatic cancer in my tweet. But, I’ll provide one example from solid tumors and I’m done with this discussion on twitter, but #HealthcareUnfiltered welcomes this debate. https://t.co/miJoYHROuN

Dec 28, 2022 · 5 likes · 20,106 followers View post →

#TumorBoardTuesday

@TumorBoardTues · X

RT @HosseinBorghaei: @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @ASCO @JCO_ASCO @MLJohnsonMD2 @BurrisSkip @RielyMD @JustinGainor @ChiFuJef…

Aug 31, 2022 · 2 shares · 5,182 followers View post →

Mike Pishvaian

@MPishvaian · X

RT @HosseinBorghaei: @TumorBoardTues @MPishvaian @JohnEbbenMDPhD @ASCO @JCO_ASCO @MLJohnsonMD2 @BurrisSkip @RielyMD @JustinGainor @ChiFuJef…

Aug 30, 2022 · 2 shares · 5,438 followers View post →

Hossein Borghaei, DO

@HosseinBorghaei · X

@TumorBoardTues @MPishvaian @JohnEbbenMDPhD @ASCO @JCO_ASCO @MLJohnsonMD2 @BurrisSkip @RielyMD @JustinGainor @ChiFuJeffYang @ECarcereny @anguspratt @KRASKickers @thenasheffect @ALKpositiveINT @EgidiusLambrech @EugeneManley @ipreeshagul @JoelNealMD @HwakeleeMD @GlopesMd @jmsuga @AstraZeneca 4/13 #TumorBoardTuesday

Aug 30, 2022 · 3 likes · 2 shares · 5,524 followers View post →

Medical Xpress

@physorg_health · X

Consolidation #nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiation for patients with NSCLC https://t.co/99q8I3c7fp https://t.co/9a63f7Oo8N

Aug 8, 2022 · 7,109 followers View post →

ほうしゃせんちりょういのアーニャ

@Anya_RadiOncol · X

@nijuoti アーニャ　4yr-OSとかんちがいしてますた N2のうち手術可能症例がどれたけいるかによりそうですね https://t.co/t4NqYkJYjb

Jun 16, 2022 · 1 like · 676 followers View post →

alberto ravaioli

@RavaioliAlberto · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer https://t.co/3JixQLrPZ7

Jun 7, 2022 · 873 followers View post →

alberto ravaioli

@RavaioliAlberto · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell … https://t.co/NVHLzpnEAx

May 26, 2022 · 873 followers View post →

Meded

@cryptovitas · X

RT @juisci: In this recent #pulmonology and #oncology article the authors compared durvalumab with placebo in patients with unresectable, s…

May 19, 2022 · 1 share · 3,178 followers View post →

Dr. Estela Rodriguez

@Latinamd · X

Now that we are considering more Stage III (N2) disease potentially resectable after chemo IO, is a good time to remind us that there is a 5yr survival advantage to chemorads followed by IO: update from PACIFIC @DavidRSpigel ▶️ 42.9% 5yr OS (HR 0.68) https://t.co/2jABzLHAE0

Apr 25, 2022 · 7,836 followers View post →

t.titova

@tatianatitova4 · X

https://t.co/CFLBJxirUi

Apr 25, 2022 · 1 like · 28 followers View post →

よし兄　Yoshi

@aminfield · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer #nsclc #Durvalumab #afterCRT https://t.co/JWQJo2uEJT

Apr 25, 2022 · 56 followers View post →

Shaheenah Dawood

@Shaheenah1 · X

RT @EiocOncology: Spiegel and Colleagues publish the 5 year update of the Pacific Trial. durvalumab still trumps observation post chemo rad…

Apr 24, 2022 · 1 share · 540 followers View post →

Excellence in Oncology Care - EIOC

@EiocOncology · X

Spiegel and Colleagues publish the 5 year update of the Pacific Trial. durvalumab still trumps observation post chemo rads in pts with unresectable stage III NSCLC . DOI https://t.co/LFAjnN3hLO https://t.co/oTYsVFtTUg

Apr 24, 2022 · 1 share · 547 followers View post →

Fumikata Hara

@9p2nNkRpjOrdvcw · X

RT @BurrisSkip: Great work : Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-…

Apr 24, 2022 · 1 share · 188 followers View post →

Skip Burris, MD

@BurrisSkip · X

Great work : Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | Journal of Clinical Oncology ⁦@DavidRSpigel⁩ ⁦@SarahCannonDocs⁩ ⁦@BandVsCancer⁩ https://t.co/DkPF9wRvaO

Apr 23, 2022 · 4 likes · 1 share · 2,817 followers View post →

rafael hamester

@HamesterRafael · X

RT @DrewMoghanaki: It remains tempting to recommend surgery for all of our pts with resectable stage III (N2) disease. Yet, I am curious if…

Mar 22, 2022 · 3 shares · 12 followers View post →

GOECP

@goecp1 · X

RT @DrewMoghanaki: It remains tempting to recommend surgery for all of our pts with resectable stage III (N2) disease. Yet, I am curious if…

Mar 22, 2022 · 3 shares · 533 followers View post →

Felipe Couñago PhD

@fcounago · X

RT @DrewMoghanaki: It remains tempting to recommend surgery for all of our pts with resectable stage III (N2) disease. Yet, I am curious if…

Mar 21, 2022 · 3 shares · 2,669 followers View post →

Drew Moghanaki

@DrewMoghanaki · X

Mar 21, 2022 · 9 likes · 3 shares · 12,958 followers View post →

169degreeswest

@169degreeswest · X

RT @DrewMoghanaki: That’s because the outcomes in the PACIFIC study were extraordinary. Even though the patients were deemed unresectable (…

Mar 10, 2022 · 1 share · 363 followers View post →

Drew Moghanaki

@DrewMoghanaki · X

Mar 8, 2022 · 6 likes · 1 share · 12,958 followers View post →

マヌーサ？

@anywere_mu · X

あ、PACIFIC試験。懐かしいと思ってしまいました。この試験は色々と大変な経験もしたけど、今となっては全てが良い思い出。経験値になった。 Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell … https://t.co/nA8dEO7dWV

Mar 8, 2022 · 1 like · 302 followers View post →

ALCASE Italia

@ALCASEItalia · X

Feb 28, 2022 · 1 like · 320 followers View post →

American Thoracic Society (ATS)

@atscommunity · X

Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in Stage III #NSCLC: https://t.co/mLxYFGDRHD

Feb 28, 2022 · 2 likes · 41,937 followers View post →

Henrique Z Fernandes

@henrique_zanoni · X

RT @JCO_ASCO:

Feb 23, 2022 · 15 shares · 77 followers View post →

tomisuke

@nextommysuke · X

RT @JCO_ASCO:

Feb 23, 2022 · 15 shares · 916 followers View post →

Andrés B.

@andres_bj87 · X

RT @JCO_ASCO:

Feb 23, 2022 · 15 shares · 91 followers View post →

Dario Arundine MD

@darioarundineMD · X

RT @JCO_ASCO:

Feb 23, 2022 · 15 shares · 16 followers View post →

ALCASE Italia

@ALCASEItalia · X

RT @JCO_ASCO:

Feb 23, 2022 · 15 shares · 320 followers View post →

Rafael Correa Cano MD, MSc.

@Rf_Correa · X

RT @JCO_ASCO:

Feb 23, 2022 · 15 shares · 1,010 followers View post →

ARYAN®

@gladeolie · X

RT @JCO_ASCO:

Feb 23, 2022 · 15 shares · 1,493 followers View post →

Amazed Radonc

@AmazedRadonc · X

RT @JCO_ASCO:

Feb 23, 2022 · 15 shares · 87 followers View post →

American Thoracic Society (ATS)

@atscommunity · X

Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in Stage III #NSCLC: https://t.co/mLxYFGDRHD

Feb 22, 2022 · 41,937 followers View post →

Stéphanie Ferland

@StphanieFerlan2 · X

RT @gusviani: The benefit remains #PACIFIC trial 5y update!!! Ph III trial 1y durvalumab (anti-PDL1) after CHRT for unresectable stage III…

Feb 19, 2022 · 8 shares · 8 followers View post →

INDoximity

@indoximity · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer https://t.co/vnUrMCpKWU #Oncology

Feb 17, 2022 · 831 followers View post →

EDGAR ANDRES PULIDO

@edgarpugil · X

RT @MLPOncoData: Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Ca…

Feb 13, 2022 · 1 share · 28 followers View post →

chadi nabhan MD, MBA, FACP

@chadinabhan · X

I love studies that report on long-term outcomes and have data on long-term follow-up. the PACIFIC trial is a perfect example of such. https://t.co/miJoYHROuN

Feb 10, 2022 · 3 likes · 20,106 followers View post →

NatureRevClinOncol

@NatRevClinOncol · X

5-year follow-up data from the PACIFIC trial of durvalumab vs placebo for stage III NSCLCs without initial disease progression following chemoradiation, reveals OS of 42.0% vs 33.4% and PFS of 33.1% vs 19.0%. The updated mOS was 47.5 vs 29.1 months: https://t.co/jpg1felrCK #lcsm

Feb 10, 2022 · 2 likes · 41,535 followers View post →

Adela

@adelapoite · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | Journal of Clinical Oncology https://t.co/hrd88uf1kC

Feb 9, 2022 · 2 likes · 1,235 followers View post →

Isaura R. Penin

@irodriguezpenin · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer https://t.co/jPMSCUDghZ

Feb 9, 2022 · 622 followers View post →

かんわラヂオ

@kanwaradio · X

ご存じの方も多いと思いますが、パシフィックの5年が出ました。3期肺癌でも長期生存できるようになってきましたね。がんには厳しく、肺や心臓に優しい照射を行っていきたいです。 https://t.co/abKHeWeK15

Feb 9, 2022 · 693 followers View post →

Carolina Polo T.

@Carpolto · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 8, 2022 · 50 shares · 424 followers View post →

OncoViews

@OncoViews · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 8, 2022 · 50 shares · 1,851 followers View post →

Ancel Julien, M.D.

@AncelJulienMD · X

RT @StephenVLiu: PACIFIC 5y update @JCO_ASCO. Phase III study of durvalumab (anti-PDL1) for 1y after chemoradiation for unresectable stage…

Feb 8, 2022 · 78 shares · 299 followers View post →

International Lung Cancer Summit

@LungSummit · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 8, 2022 · 50 shares · 2,671 followers View post →

filippo masini

@filimasini · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 8, 2022 · 50 shares · 770 followers View post →

ALCASE Italia

@ALCASEItalia · X

Dal PACIFIC study (Durvalumab dopo radio-chemioterapia per il NSCLC in stadio III): il 42,9% dei pazienti assegnati in modo casuale a Durvalumab è ancora vivente a 5 anni e il 33,1% di questi é privo di progressione della malattia. https://t.co/S0DxroG1mC

Feb 7, 2022 · 1 like · 320 followers View post →

Andres F. Cardona

@AndresFCardonaZ · X

RT @StephenVLiu: PACIFIC 5y update @JCO_ASCO. Phase III study of durvalumab (anti-PDL1) for 1y after chemoradiation for unresectable stage…

Feb 7, 2022 · 78 shares · 8,813 followers View post →

filippo masini

@filimasini · X

RT @StephenVLiu: PACIFIC 5y update @JCO_ASCO. Phase III study of durvalumab (anti-PDL1) for 1y after chemoradiation for unresectable stage…

Feb 7, 2022 · 78 shares · 770 followers View post →

Ahmed Tayel

@AhmedTayel13 · X

RT @MSK_RadOnc:

Feb 5, 2022 · 3 shares · 362 followers View post →

VNardone

@Valerio_Nardone · X

RT @MSK_RadOnc:

Feb 5, 2022 · 3 shares · 1,055 followers View post →

Rodrigo Hepp

@rheppd · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 5, 2022 · 23 shares · 43 followers View post →

Pearl David

@PearlDa48807148 · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 5, 2022 · 23 shares · 995 followers View post →

Gkika Eleni

@GkikaEleni2 · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 5, 2022 · 23 shares · 114 followers View post →

Beatriz Álvarez

@BeaAlvarezRguez · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 131 followers View post →

Pran&Vida

@Pranyvida · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 4, 2022 · 50 shares · 45 followers View post →

Seán Walsh

@Walshsharp · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 136 followers View post →

Emma D'Ippolito

@emmadippolito · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 196 followers View post →

Ancel Julien, M.D.

@AncelJulienMD · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 4, 2022 · 50 shares · 299 followers View post →

Raj Singh, MD

@Raj_Singh_MD · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 1,059 followers View post →

Gaia Piperno

@GaiaPiperno · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 511 followers View post →

MacArena

@MacArena_Salud · X

RT @dmavicente: https://t.co/BatRmtCUpI

Feb 4, 2022 · 1 share · 513 followers View post →

Andrés Ocaña

@andresocanacope · X

RT @dmavicente: @rafarcipe @saludand https://t.co/BatRmtCUpI

Feb 4, 2022 · 1 share · 20,737 followers View post →

Andres F. Cardona

@AndresFCardonaZ · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 4, 2022 · 50 shares · 8,813 followers View post →

OncoAlert

@OncoAlert · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 39,833 followers View post →

Maria Sierra Garcia

@MsgSierra · X

RT @DrJNaidoo: 5-yr PACIFIC Update: Durva After ChemoRT in Stage III NSCLC @JCO_ASCO - 709 pts (durva 472; pbo 236) - mfollow-up: 34.2mo -…

Feb 4, 2022 · 40 shares · 165 followers View post →

Simon Boeke

@BoekeSimon · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 545 followers View post →

Dr. Bivas Biswas

@DrBivas · X

RT @StephenVLiu: PACIFIC 5y update @JCO_ASCO. Phase III study of durvalumab (anti-PDL1) for 1y after chemoradiation for unresectable stage…

Feb 4, 2022 · 78 shares · 849 followers View post →

Journal of Clinical Oncology

@JCO_ASCO · X

RT @MSK_RadOnc:

Feb 4, 2022 · 3 shares · 54,525 followers View post →

Andrea R. Filippi

@AndrearicFili · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 1,630 followers View post →

Daniel Moore Palhares

@DMoorePalhares · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 4, 2022 · 50 shares · 499 followers View post →

Memorial Sloan Kettering Radiation Oncology

@MSK_RadOnc · X

Feb 4, 2022 · 11 likes · 3 shares · 4,422 followers View post →

Cancer Library VCC

@VCCLibrary · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer https://t.co/YSGa0MjpZC #lungcancer

Feb 4, 2022 · 1,279 followers View post →

Paul Sargos

@PaulSargos · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 1,985 followers View post →

Patrick Murray

@ugm6pfm · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 668 followers View post →

Sophia Kamran, MD

@sophia_kamran · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 3,776 followers View post →

Juan Felipe Castilla

@juancastilla_ · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 4, 2022 · 50 shares · 167 followers View post →

Cancer Watch

@Cancer_watch · X

RT @DrJNaidoo: 5-yr PACIFIC Update: Durva After ChemoRT in Stage III NSCLC @JCO_ASCO - 709 pts (durva 472; pbo 236) - mfollow-up: 34.2mo -…

Feb 4, 2022 · 40 shares · 72 followers View post →

Bourbonne Vincent

@BourbonneV · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 175 followers View post →

Matthias Guckenberger

@Mat_Guc · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 5,658 followers View post →

Felipe Couñago PhD

@fcounago · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 2,669 followers View post →

LMU Radiation Oncology

@LMU_RadOnc · X

RT @StephenVLiu: PACIFIC 5y update @JCO_ASCO. Phase III study of durvalumab (anti-PDL1) for 1y after chemoradiation for unresectable stage…

Feb 4, 2022 · 78 shares · 500 followers View post →

Jackie Aredo

@JackieAredoMD · X

RT @DrJNaidoo: 5-yr PACIFIC Update: Durva After ChemoRT in Stage III NSCLC @JCO_ASCO - 709 pts (durva 472; pbo 236) - mfollow-up: 34.2mo -…

Feb 4, 2022 · 40 shares · 164 followers View post →

Prof Ananya

@achoud72 · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 2,612 followers View post →

Amir Safavi

@safaviaa · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 1,036 followers View post →

Antonio Torres

@viniciu_antonio · X

RT @finn_corinne: Delighted to share the PACIFIC 5 yr survival update ▶️median FU 34.2 months ▶️OS HR, 0.72; 95% CI 0.59-0.89; median, 47…

Feb 4, 2022 · 23 shares · 340 followers View post →

Corinne Faivre-Finn

@finn_corinne · X

Feb 4, 2022 · 99 likes · 23 shares · 4,600 followers View post →

Jie Wang

@JieWang27523466 · X

RT @DrJNaidoo: 5-yr PACIFIC Update: Durva After ChemoRT in Stage III NSCLC @JCO_ASCO - 709 pts (durva 472; pbo 236) - mfollow-up: 34.2mo -…

Feb 4, 2022 · 40 shares · 62 followers View post →

david vicente baz

@dmavicente · X

https://t.co/BatRmtCUpI

Feb 4, 2022 · 1 like · 1 share · 11,915 followers View post →

david vicente baz

@dmavicente · X

@rafarcipe @saludand https://t.co/BatRmtCUpI

Feb 4, 2022 · 1 like · 1 share · 11,915 followers View post →

Note Chawalit

@notemdcn · X

RT @DrJNaidoo: 5-yr PACIFIC Update: Durva After ChemoRT in Stage III NSCLC @JCO_ASCO - 709 pts (durva 472; pbo 236) - mfollow-up: 34.2mo -…

Feb 4, 2022 · 40 shares · 127 followers View post →

Chiara CATANIA

@ChiaraCATANIA4 · X

RT @StephenVLiu: PACIFIC 5y update @JCO_ASCO. Phase III study of durvalumab (anti-PDL1) for 1y after chemoradiation for unresectable stage…

Feb 4, 2022 · 78 shares · 1,161 followers View post →

Sergio Casillas

@scasillasmd · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 4, 2022 · 50 shares · 104 followers View post →

Guillaume Le Bihan

@GuillaumeLB9 · X

RT @StephenVLiu: PACIFIC 5y update @JCO_ASCO. Phase III study of durvalumab (anti-PDL1) for 1y after chemoradiation for unresectable stage…

Feb 4, 2022 · 78 shares · 121 followers View post →

manolo_segura

@manolosegura8 · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 4, 2022 · 50 shares · 131 followers View post →

FarmaOnco

@FarmaOnco · X

RT @gedefo_sefh: Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #LungCa…

Feb 4, 2022 · 1 share · 2,634 followers View post →

ほーくあい MD/PhD@Breast Oncology

@tkdmHawkeye · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer https://t.co/2Vbmowqbeo ケモラジ後デュルバの5年後OS

Feb 3, 2022 · 976 followers View post →

Dr Shivam (MS, M.Ch Surg Onco)

@CancerCentral2 · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 1,239 followers View post →

Joel YR

@YnfaYr · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 116 followers View post →

Adela

@adelapoite · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 1,235 followers View post →

Lourdes García

@lourdesgs1980 · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 1,746 followers View post →

Inma

@inmasve · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 104 followers View post →

NACHO CHACÓN

@PrimeroMARCUS · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 995 followers View post →

Felipe Magaldi

@DrFelipeMagaldi · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 132 followers View post →

Mariángel Gil

@Magil2006 · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 1,304 followers View post →

Alfonso Bozzano

@BozzanoAlfonso · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 84 followers View post →

Agnese Prisco

@PriscoA78 · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 94 followers View post →

Total Health | Oncology

@TotalHealthConf · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 2,540 followers View post →

Augusto_Valdivia

@Augusto_AVB · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 169 followers View post →

Idoia Morilla

@MorillaIdoia · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 280 followers View post →

Erick Maya

@Ericck_Maya · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 160 followers View post →

Camillo Porta

@CPRT65 · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 666 followers View post →

Eduard Centeno

@segol60 · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 409 followers View post →

MLP Oncología

@MLPOncoData · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer https://t.co/Gqp752KwWq

Feb 3, 2022 · 1 like · 1 share · 704 followers View post →

Nauman Saleem Siddiqui, MD MPH FACP

@HemOnc_AI · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 325 followers View post →

Abrahams Ocanto

@abraocantoMD · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 603 followers View post →

Martín Lázaro

@mlazqui · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 4,226 followers View post →

Enlightening Results

@GraceCordovano · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 8,396 followers View post →

Irene Mangues

@IreneMangues · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 1,301 followers View post →

Iñigo Vazquez-Aldana

@inigovaa · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 296 followers View post →

Felipe Couñago PhD

@fcounago · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 2,669 followers View post →

Journal of Clinical Oncology

@JCO_ASCO · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 54,525 followers View post →

Mario Garcia

@garcho1478 · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 51 followers View post →

Mutlu Hizal

@drmutluhizal · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 610 followers View post →

Elene Mariamidze

@EMariamidze · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 2,467 followers View post →

Gaby Regalado

@gabyregal · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 1,094 followers View post →

Alan Reyes-M.D

@dralanreyesonco · X

RT @DrYukselUrun: PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 50 shares · 1,351 followers View post →

Yüksel Ürün

@DrYukselUrun · X

PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #lungcancer :

Feb 3, 2022 · 147 likes · 50 shares · 9,770 followers View post →

Feedkast Medical

@FeedkastMedical · X

Check out, “Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer,” from @JCO_ASCO #lcsm https://t.co/CT3NwomTBh Keep up to date with our #NSCLC Influencers feed on #Feedkast https://t.co/PJ1QxsHYLq

Feb 3, 2022 · 447 followers View post →

GEDEFO

@gedefo_sefh · X

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell #LungCancer https://t.co/apAk0Ijmwj

Feb 3, 2022 · 1 share · 5,430 followers View post →

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Durvalumab Extends Survival in Stage III Non-Small Cell Lung Cancer

Long-Term Survival Benefits of Durvalumab in Stage III Lung Cancer